Published every week since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.
The authors provide an overview of the intrinsic functional properties of luminal progenitor cells, and address their relevance in mouse and human prostate pathophysiology.
The use of genomic testing for prostate cancer continues to grow; however, utilization remains institutionally dependent. Scientists review current tissue-based markers and comment on current use with active surveillance and prostate MRI.
Investigators provide a detailed overview of the current knowledge of the role of the human microbiome in prostate cancer development, progression, and treatment response.
[Journal of Experimental & Clinical Cancer Research]
Profound Medical Corp. announced that the first patients have been treated in the Level 1 ‘CAPTAIN’ trial. CAPTAIN (A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants with Localized Prostate Cancer) is a prospective, multi-centre randomized controlled trial of 201 patients aimed at comparing the safety and efficacy of the TULSA procedure with radical prostatectomy in men with organ-confined, intermediate-risk, Gleason Score 7 prostate cancer.
Researchers explored the prognostic potential and the functional role of microRNAs in localized prostate cancer and their relation to nodal metastasis.
Investigators assessed the stage-specific expression of zinc transporters (ZNTs) belonging to the ZNT (SLC30A) and Zrt- and Irt-like protein (SLC39A) solute-carrier family in the prostate tissues of different genetically engineered mouse models of prostate cancer, their age-matched wild-type controls, and 104 prostate core biopsies from human patients with different pathological lesions.
Scientists evaluated growth differentiation factor-15 (GDF15) function using in vivo preclinical prostate cancer (PCa)-bone metastasis mouse models and an in vitro bone cell coculture system and suggested that PCa-secreted GDF15 promoted bone metastases and induced bone microarchitectural alterations in a preclinical xenograft model.
Using human cell lines that represent androgen-independent or -sensitive prostate cancer, the authors showed that mitochondrial Rho GTPase 2 (MIRO2) depletion impaired cell growth, colony formation, and tumor growth in mice.
Abiraterone, an inhibitor of the steroidogenic enzyme CYP17A1, has been demonstrated to reduce adrenal androgen synthesis and prolong CRPC patient survival. To study mechanisms of resistance to castration and abiraterone, researchers created coculture models using human prostate and adrenal tumors.
Combination therapy with the transforming growth factor-β receptor I kinase inhibitor SD-208 and a toll-like receptor-7/8 agonist resiquimod was examined along with serum-derived exosomes as versatile carriers and may serve as a promising strategy to treat melanoma and prostate cancer.
Investigators studied the effect of co-treatment of caffeic acid phenethyl ester (CAPE) and gamma radiation on androgen-independent DU145 and PC3 cells. The combination treatment sensitized prostate cancer cells to radiation in a dose-dependent manner. The radiosensitizing effect of CAPE was observed in both cell lines.
